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Summary Objectives: Overuse of acid suppressive therapy (AST) has been reported in
hospitalised patients, but the use in specific patient categories is unexplored. We
assessed the use of and indication for AST and upper endoscopic investigations in
hospitalised patients on a pulmonary ward compared with patients on other wards.
Methods: 301 patients were enrolled in the study. 162 were hospitalised on a
pulmonary ward with a control group consisting of 139 from both a surgical and
general internal medicine ward. Adequate indications for AST were those strongly
supported by medical literature.
Results: Among the 301 patients enrolled, 132 (44%) used AST. 78 (59%) had no
adequate indication for AST. On the pulmonary ward 79 (49%) patients used AST,
compared to only 10 (20%) on the internal medicine ward (Po0.05). On the
pulmonary ward 68% of the patients had no adequate indication for AST, which was
more common than inappropriate use of ASTon the control wards (Po0.05). The most
common inadequate indication for AST was peptic ulcer prophylaxis during
corticoidsteroid therapy.
Conclusion: In hospitalised patients a significant overuse of AST was observed,
particularly among pulmonary patients. More adequate use of AST can contribute to
substantial savings for the health-care system.
r 2003 Elsevier Ltd. All rights reserved.
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Introduction
Acid suppressive drugs are amongst the most
extensively used medications in hospitalised pa-
tients 1–4 as well as in primary care.5 These drugs
constitute a major economic burden for the health-
care system in many countries. In a study carried
out in Connecticut, US, as many as 54% of all
hospitalised patients received acid suppressive
therapy (AST).1 This study also showed that a large
proportion of the hospitalised patients who re-
ceived AST did not have an adequate indication for
the use of these drugs.1 Other studies have shown
that an acid suppressive drug often is prescribed for
minor symptoms and without clear indications.6,7
In the United States non-gastroenterologists are
responsible for more than 80% of prescriptions
of proton pump inhibitors (PPIs).8
A survey of statistics from the Sahlgrenska
University Hospital Pharmacy demonstrated that
the pulmonary ward was among the largest
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consumer of AST at the hospital. The use of AST in
patients with pulmonary diseases has to our knowl-
edge not previously been studied. Our objective
therefore was to investigate the use of AST on a
pulmonary ward in comparison with other types of
wards in order to compare patients with pulmonary
diseases with patients with other chronic diseases.
We also wanted to assess the indications for AST
and whether these indications were adequate or
not. Further aims were to assess the proportion of
patients who had undergone upper gastrointestinal
gastroscopy and/or 24 h esophageal pH measure-
ments. Furthermore, we wanted to see the ratio
between the use of H-2 receptor antagonists
and PPIs.
Materials and methods
Subjects
Sahlgrenska University Hospital is a 2700-bed
metropolitan teaching hospital, that serves ap-
proximately 700,000 inhabitants in the Gothenburg
region in Sweden.
301 patients were enrolled, of which 162 patients
were hospitalised on the pulmonary ward, of which
only patients with pulmonary diseases were en-
rolled. Of the remaining 139 patients, 88 were
hospitalised on the surgical ward and 51 were
hospitalised on the general internal medicine ward.
The Ethical Committee of the Medical Faculty at
the University of G .oteborg approved the study.
Experimental design
This study was conducted in two phases. In the first
phase patients were enrolled from four wards
including two surgical wards, one pulmonary ward
and one general internal medicine ward. These
wards were surveyed on three randomly chosen
days and on three different occasions from January
to April 2001. During the second phase, all patients
on the pulmonary ward were continuously investi-
gated during the period from August to October
2001. The first phase was a pilot study and the
second phase was only performed on pulmonary
patients but with exactly the same methodology.
Use of AST was defined as any treatment with
either PPI or H-2-receptor antagonist, regardless of
dose regimen. Adequate indications for AST were
considered to be these listed in the Swedish
National Formulary (FASS) under the subheading
of acid suppressive drugs as shown in Table 1. In the
2002 version of the Swedish National Formulary,
treatment of ulcer-like symptoms is listed as an
indication for omeprazole (perhaps based upon the
results of the study by Talley et al.9), showing a
significant benefit for the drug compared with
placebo in patients with ulcer-like dyspepsia. Apart
from the above indications one more indication was
considered adequate, i.e. GI haemorrhage prior to
endoscopy. Although AST treatment in the last
mentioned group of patients is not always neces-
sary it is first evident after the endoscopy who is in
need of AST and who should continue AST due to
bleeding peptic ulcer for example. The possibility
of a bleeding ulcer in a patient in hospital waiting
for an upper endoscopy was therefore considered
to be an adequate indication and is a common
praxis in most hospitals. Peptic ulcer in patients
who had not been investigated for helicobacter
pylori (HP) was considered as an inadequate
indication for AST as was long-term treatment of
a gastric ulcer without a control gastroscopy.
Information was collected from medical records
and by patient interviews during their hospitalisa-
tion. If information about indication for ASTwas not
available in the patient’s medical records the
patients were then interviewed. The following data
was collected: demographic information, dose of
AST, indications for AST, and endoscopy report or
other relevant investigations (24-h pH esophageal
measurements). Patients readmitted during the
study period were not re-enrolled in the study.
Statistical analysis
Fisher’s Exact Test was used for comparison of AST
use and the frequency of inappropriate AST
ARTICLE IN PRESS
Table 1 Adequate indications for AST.
Peptic ulcer (gastric and duodenal).
Long-term treatment of chronic, non-HP related peptic ulcer.
GERD with and without esophagitis.
Prevention of NSAID-induced ulcer and NSAID-related symptoms.
Symptomatic treatment of ulcer-like symptom.
Upper GI bleeding (before endoscopy).
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between different patient groups, and in compar-
ison of the frequency of gastroscopy. Results were
expressed as mean and standard error of the mean.
Significance was accepted at the 5% level.
Results
Patient’s characteristics
The mean age of the 301 patients included in the
study was 6971 years with 135 (45%) of the
patients being male. Gender distribution, mean
age and age range were similar in the different
groups (Table 2). Admitting diagnoses for hospita-
lised patients under AST are shown in Table 4. Of
the patients using AST, 44% were male and 56%
were female. Patients using AST had a mean age of
7071 years (Table 3).
Use of acid suppressive therapy
A total of 132 patients (44%) of the 301 patients
were receiving PPIs or H-2-receptor antagonists
during the study period. On the pulmonary ward 79
(49%) of the patients used AST (53% in phase one
and 47% in phase two (NS)). On the surgical wards
43 (49%) of the patients used AST, whereas only 10
(20%) of the patients on the general internal
medicine ward received AST. A higher proportion
of hospitalised patients with pulmonary diseases
used AST compared with patients hospitalised on
the general internal medicine ward (Po0:01).
There was no significant difference between
pulmonary patients and patients hospitalised on
the surgical ward in terms of the proportion of
patients using AST.
Of the patients receiving AST, 88 (67%) were
prescribed AST prior to admission, whereas 44
(33%) began therapy during hospitalisation. There
was no significant difference between the distribu-
tion of adequate and inadequate indications among
patients already taking AST on admission compared
to those who commenced AST during hospitalisa-
tion. Twenty-three patients (17%) received their
acid suppressive drug through intravenous admin-
istration, whilst the remainder of the 109 patients
were treated orally.
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Table 2 Characteristics of the study population.
All inpatients Pulmonary ward Surgical ward Internal medicine ward
Gender
Female 166 85 52 29
Male 135 77 36 22
Mean age 69.2 (19–98) 68.8 (28–95) 68.1 (26–96) 72 (19–98)
Table 3 Characteristics of patients under AST.
All inpatients Pulmonary ward Surgical ward Internal medicine ward
Gender
Female 74 44 23 7
Male 58 35 20 3
Mean age 70 (28–93) 67.8 (28–89) 70.6 (37–93) 77.7 (59–92)
Table 4 Admitting diagnoses for patients under AST.
Diagnosis Number of patients
(%) N ¼ 132
COPD 43 (33%)
Lung cancer 20 (15%)
Othern 20 (15%)
GI-cancer 12 (9%)
Peptic ulcer 9 (7%)
GI-bleeding 8 (6%)
Abdominal pain UNS 6 (5%)
Pancreatitis 4 (3%)
Asthma bronchiale 3 (2%)
GI-symptomsw 3 (2%)
Tuberculosis 2 (1.5%)
Diverticulitis 2 (1.5%)
nOther includes: pneumonia, intoxication, appendicitis,
chest pain, sepsis, collapsed vertebrae, nephrolithiasis,
renal failure, neoplasia, cystic fibrosis, breast cancer,
chronic myeloid leukaemia.
wGI-symptoms include: vomiting, ileus, cholecystitis.
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Type of acid suppressive therapy
The most frequently used type of medication were
PPIs, used in 126 (95%) of the cases. A total of 6
patients (5%) received H-2-antagonists. The most
frequently used drug was lanzoprazole, which was
used in 59 patients (45%), followed by omeprazole
in 52 (39%), esomeprazole in 10 (7%), and panto-
prazole in 5 patients (4%). The most common
dosage of lanzoprazole was 30mg daily. Of the
6 patients using H-2-receptorantagonists, all
received ranitidine.
Indications for acid suppressive therapy
Of the 132 patients receiving AST therapy, 54 (41%)
had adequate indications for the use of AST,
whereas 78 patients (59%) lacked an adequate
indication. The proportion of patients with
inadequate use of AST was higher among
patients hospitalised on the pulmonary ward,
compared with the control wards (68% vs. 47%
Po0:05) (Fig. 1).
The pulmonary ward was studied on two occa-
sions, initially on three randomly chosen days, and
then continuously for 9 weeks. The results from
both occasions were quite similar. On the first
occasion, the frequency of AST usage was 53%,
whereas on the second occasion 47% of the patients
were using AST. On the first occasion, 70% of the
patients had inadequate indication for AST usage
and on the second occasion 65% of the patients had
no adequate indication (NS).
The most common adequate indication for AST
among patients on the pulmonary ward and on the
general internal medicine ward was gastroesopha-
geal reflux disease (GERD), which represented the
indication in 15 (11%) of the patients (Fig. 2), whilst
peptic ulcer was the most common adequate
indication on the surgical wards. Ulcer prophylaxis
during treatment with corticosteroids was the most
frequent inadequate use and was observed in 17
patients (13%) (Fig. 3), of whom 15 were hospita-
lised on the pulmonary ward. The most common
inadequate indication for AST usage on the other
wards was stress ulcer prophylaxis following in-
tensive care unit treatment, which was not
discontinued when the patients were transferred
to general wards, and represented 12 of the cases
(Fig. 3). The indications for prescribing AST are
shown in Table 5.
Investigations
Of the 132 patients receiving AST, 56 patients (42%)
had undergone gastroscopy. On the pulmonary ward
only 25 patients (32%) had been investigated by
gastroscopy, compared with the other wards where
31 of 53 patients (58%) had undergone gastroscopy
(Po0:05). If those who were on prophylactic
treatment with corticosteroids (perhaps not in
need of a gastroscopy) were excluded, no signifi-
cant difference was observed in the number of
patients undergoing gastroscopy in the two groups.
Endoscopic results are shown in Table 6. Patients
who had undergone gastroscopy were more likely to
have an inadequate indication for ASTas opposed to
patients who had not undergone gastroscopy
Po0:01: Of the patients who were on long-term
treatment for peptic ulcer, none had received HP
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Figure 1 Proportion of adequate and inadequate indications for AST. The black bars show adequate indications and the
grey bars show inadequate indications. Po0:05 compared to control wards.
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eradication at any time. However, it is difficult to
exclude this possibility as some of the patients may
not have been were aware of having received this
kind of treatment. Only one patient had undergone
24-h esophageal pH measurements.
Discussion
Previous studies addressing indications for AST have
focused on determining the use of AST amongst
hospitalised patients in general.1–3 These studies
have demonstrated a large and often inappropriate
prescribing of AST to hospitalised patients as well
as to patients in primary care.1–5 Information about
the use of AST in specific patient groups, such as
patients with pulmonary diseases is limited. The
current study demonstrated a high consumption of
AST in hospitalised patients, especially patients
with pulmonary diseases. A higher proportion of the
pulmonary patients lacked an adequate indication
for the use of AST in comparison with patients
hospitalised on the surgical wards and general
internal medicine ward.
The most common inadequate indication in the
present study was ulcer prophylaxis during corti-
costeroid treatment among patients on the
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Figure 3 Proportion of total AST users shown per inadequate indication for the different wards. Black bars represent
the pulmonary patients, striped bars represent the surgical patients and white bars represent the general internal
medicine patients. *Peptic ulcer: patients who were on long-term AST without a diagnostic work-up for HP.
Figure 2 Proportion of total ASTusers shown per adequate indication for the different wards. Black bars represent the
pulmonary patients, striped bars represent the surgical patients and white bars represent the general internal medicine
patients.
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pulmonary ward. Oral corticosteroids are among
the most widely used drugs in treatment of patients
with pulmonary diseases, especially patients with
chronic obstructive pulmonary disease (COPD) as
was the case in the present study. Previously, use of
corticosteroids has been reported to be associated
with the development of peptic ulcer, although
only in a small minority of patient’s.10 However, it
has since then been well documented that corti-
costeroids do not increase the risk of peptic
ulcer.11–13 A meta analysis conducted by Conn and
Poyard demonstrated no increased risk for peptic
ulcer related to corticosteroid use.12 Piper et al
demonstrated that only patients on corticosteroids
concomitantly treated with NSAID were at in-
creased risk for peptic ulcer compared with
patients taking only corticosteroids.13 On the
surgical and general internal medicine wards stress
ulcer prophylaxis was the most common inadequate
indication for AST.
Abdominal pain was another common inadequate
indication and in many cases these patients had
been on long-standing treatment with AST without
the treatment’s efficiency being evaluated. Peptic
ulcer disease without follow-up control was also
common among the inadequate indications in all
patient groups. Patients with duodenal ulcer do not
need gastroscopy to control ulcer healing but need
to be tested for HP. Treatment of gastric ulcer
should always be followed by a control gastroscopy
in order to ensure healing and to rule out
malignancy according to clinical guidelines.14
Although we are currently aware that HP plays a
critical role in the pathogenesis and relapse of
peptic ulcer, both effective gastric acid suppression
and antibiotic therapy is required for prompt ulcer
healing and HP eradication.14,15 It has recently
been shown that HP eradication and, ulcer healing
in patients with peptic ulcer makes further AST
unnecessary.15
The number of patients who received AST and
were investigated by gastroscopy was low, with a
large difference between wards. On the pulmonary
ward, only 32% of the patients receiving AST had
undergone a gastroscopy, whilst on the other wards
the percentage of patients who had undergone a
gastroscopy was 58%, which was a significantly
higher proportion. The reason behind this differ-
ence was not addressed in the present study, but it
is conceivable that patients with pulmonary dis-
eases have a poorer health status, making it
difficult to undergo such a procedure. Not all
patients receiving PPI as symptomatic treatment
of dyspepsia need to undergo a gastroscopy prior to
AST. However, patients above 50–55 years should
undergo a gastroscopy to rule out other serious
diseases.16 In the present study most of the
pulmonary patients were older than 50 years.
A common indication for treatment with AST in
patients on the pulmonary ward was GERD, which is
also a common indication in the overall use of
AST.17 A contributing factor to this may be that
drugs commonly used by pulmonary patients, such
as theophylline, may decrease the pressure of the
lower esophageal sphincter (LESP).18 However, the
effect of theophylline on LESP is still controver-
sial.19–21 The association between GERD and re-
spiratory symptoms is well recognised in the setting
of asthma,22–24 however research has not yet found
a ‘‘cause and effect’’ relationship.23 It is estab-
lished that the prevalence of weekly GERD
symptoms in patients with asthma is higher than
in non-asthmatic subjects.22 In contrast to asthma
the prevalence of GERD symptoms is not well
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Table 5 Recorded indications for AST.
Reason for AST Number of patients
(%) (N ¼ 132)
Corticosteroid prophylaxis 17 (13%)
GERD 15 (11%)
Peptic ulcern 15 (11%)
Abdominal pain 13 (10%)
Stress ulcer prophylaxis 12 (9%)
Ulcer-like symptoms 9 (7%)
NSAID-prophylaxis 9 (7%)
Ulcerw 8 (6%)
No reasons found 7 (5.5%)
Upper GI bleeding 6 (4.5%)
Otherz 21 (16%)
nPeptic ulcer includes: Duodenal and gastric ulcer.
wUlcer includes: Patient whom has had an ulcer, without
follow-up control.
zOther includes: Hiatal hernia, anaemia, NSAID prophy-
laxis without NSAID therapy, gastritis, gastroenteritis.
Table 6 Endoscopy results.
Endoscopic diagnosis Number of patients
(N ¼ 56)
Normal 15
Peptic Ulcer 11
Othern 10
Unknown 9
Cancer 5
Hiatal hernia 4
Esophagitis 2
nOther includes: malignancy, duodenitis, varix bleeding,
erythema.
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established in patients with COPD. A recent study
showed that patients with COPD had a higher
prevalence of GERD symptoms than a control group
consisting of patients attending a general medicine
clinic without respiratory complaints.25 More stu-
dies are warranted on the relationship between
GERD and COPD.
Proton pump inhibitors were the dominating acid
suppressive drugs in our study. Only 5% of the
enrolled patients received H-2-receptor antago-
nists. Other studies conducted in the US and
England on the usage of AST, have demonstrated
that H-2-receptor antagonists were more fre-
quently used than PPIs.1,2 This is probably ex-
plained by varying prescription traditions in
different countries. Why PPI have been the
dominating acid suppressive drugs in Sweden may
be due to the fact that the first PPI (omeprazole)
was developed in Sweden. Effective marketing may
also be an important factor. A considerable
economic benefit is likely to be gained by the
health care system by prescribing H-2-receptor
antagonists instead of PPI. Although it would have
been interesting to see how many of our patients
who had been treated with an H-2-receptor
antagonist prior to PPI therapy, this information
was not available in our study.
Difficulties in discontinuation of AST might
contribute to the high prevalence of AST in these
patients. Recently it has been shown in healthy
subjects that rebound acid hypersecretion after
discontinuation of ASTwas associated with dyspep-
sia.26 Whether or not this may play a role for the
high prevalence of long-term AST is unclear, but
clearly warrants further studies.
From the results of our study we can conclude
that there was a significant overuse of AST in
hospitalised patients, particularly among patients
with pulmonary disease. More adequate prescribing
of AST such as avoiding AST as ulcer prophylaxis
among corticosteroid treatment and unmotivated
stress ulcer prophylaxis can lead to substantial
savings. This study has demonstrated that there is a
need for improvement in clinical practice regarding
the use of AST.
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